Considering AP-1 targets several critical genes involved in IL-17 and TNF signaling pathways, we have sufficient confidence to speculate that AP-1 has excellent potential to be a new therapeutic target for the treatment of psoriasis through regulating the skin immune microenvironment and proliferation of epidermal keratinocytes. The gene discussed is IL17A; the disease is psoriasis.